Emerging Noninvasive Treatments of Nonmelanoma Skin Cancers

Emily Tongdee, MD; Corinna Eleni Psomadakis, MBBS; Pavan Paka, MBBS; Nadeem Marghoob, BS; Orit Markowitz, MD

Nonmelanoma skin cancer (NMSC) is the most common malignancy worldwide, and its incidence continues to increase. Originally, treatment options for NMSCs largely relied on destructive and surgical methods. Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) commonly are treated with cryosurgery; electrodesiccation and curettage; or more definitive surgical options, including excision and Mohs micrographic surgery (MMS). Over time, topical agents such as 5-fluorouracil, imiquimod, ingenol mebutate, and various forms of aminolevulinic acid (ALA) for photodynamic therapy (PDT) were included for superficial lesions as well as field treatment. The development of oral hedgehog (Hh) inhibitors, such as vismodegib, offered a promising alternative to patients with advanced disease. Each treatment has its own specific indications and side effects; thus, there is always room for novel therapeutic approaches. We review new and potential treatments for NMSCs since 2018 including topical sonidegib, cemiplimab, taladegib, posaconazole, radiation therapy (RT), combination RT with vismodegib, PDT, and laser therapies.


Nonmelanoma skin cancer (NMSC) is the most common malignancy worldwide, and its incidence continues to increase. More than 5 million NMSCs are estimated to occur annually in the United States alone. The rising incidence of NMSCs highlights the importance of investigating additional treatment options with fewer side effects, better cosmetic outcomes, and better efficacy. Originally, treatment options for NMSCs largely relied on destructive and surgical methods. Basal cell carcinoma and SCC commonly are treated with cryosurgery; electrodesiccation and curettage; or more definitive surgical options, including excision and Mohs micrographic surgery (MMS). Over time, topical agents such as 5-fluorouracil, imiquimod, ingenol mebutate, and various forms of aminolevulinic acid (ALA) for photodynamic therapy (PDT) were included for superficial lesions as well as field treatment. The development of oral hedgehog (Hh) inhibitors, such as vismodegib, offered a promising alternative to patients with advanced disease. Each treatment has its own specific indications and side effects; thus, there is always room for novel therapeutic approaches. We review new and potential treatments from 2018 and beyond. Although only 5% of SCCs become locally advanced, recur, or metastasize, and 0.4% to 0.8% of BCCs progress to advanced disease, many of the newer studies target advanced NMSCs, given their life-threatening and debilitating nature. Similarly, the incidence of nevoid basal cell carcinoma (NBCC) syndrome is as low as 1 in 57,000 to 1 in 164,000 but continues to be studied because of its morbidity and the potential to contribute new treatment options for BCC in the general population.

Topical Therapy

Sonidegib—Basal cell carcinoma proliferation is a result of an unregulated Hh pathway that is initiated when the
Hh ligand binds to the patched 1 protein (PTCH1).\textsuperscript{7–11} Patched 1 protein normally inhibits the smoothened (SMO) transmembrane receptor protein, decreasing the signaling cascade. In BCCs, there is a loss of PTCH1 function, effectively increasing the Hh pathway activity. Sonidegib is an Hh inhibitor that in turn prevents inhibition of PTCH1 in an attempt to reregulate the pathway.\textsuperscript{7–11} Although sonidegib is known for its 2015 approval by the US Food and Drug Administration (FDA) as a systemic therapy for locally advanced BCCs,\textsuperscript{12} one study investigated a topical formulation on 8 patients with NBCC syndrome.\textsuperscript{13} Patients were treated twice daily with sonidegib cream 0.75% for 4 weeks in a double-blind, randomized, vehicle-controlled study. A total of 27 BCCs were randomized and treated with either vehicle or sonidegib. A biopsy was taken at the end of the study of 1 sonidegib-treated and 1 vehicle-treated BCC lesion per patient. Of the 13 sonidegib-treated BCC lesions, 3 (23.1%) showed complete response, 9 (69.2%) showed partial response, and 1 (7.7%) showed no response vs 13 of 14 (92.8%) lesions that did not respond to the vehicle. Patients tolerated the treatment well without skin irritation or signs of local or systemic side effects.\textsuperscript{13} Topical sonidegib should be further investigated as an adjunct or in different vehicles given the successful regression of BCCs and its minimal side-effect profile.

**Systemic Therapy**

Cemiplimab—Cemiplimab is a human monoclonal antibody against programmed death receptor 1 (PD-1) that was FDA approved in September 2018 for the treatment of metastatic cutaneous SCC.\textsuperscript{14} Programmed death receptor 1 is found on T lymphocytes, B lymphocytes, and macrophages, which normally assist in the immune response to tumor cells. However, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2) are found on tumor cells and bind to PD-1. Cemiplimab prevents PD-1 from binding to PD-L1 and PD-L2, allowing an appropriate immune response.\textsuperscript{14,15} A phase 1 clinical trial of cemiplimab showed a 50% (13/26) response rate.\textsuperscript{16} The phase 2 trial included patients with advanced SCC, but the primary analysis only considered patients with metastatic SCC. Phase 2 results showed a 47.5% (28/59) response rate. Patients received intravenous cemiplimab 3 mg/kg once every 2 weeks for up to 48 weeks in phase 1 and up to 96 weeks in phase 2. Both phases of the trial showed a response to treatment lasting longer than 6 months in more than 50% of patients. The most common adverse events were diarrhea, fatigue, nausea, constipation, and rash.\textsuperscript{16}

Although immune-mediated adverse reactions are rare, they can occur given cemiplimab’s mechanism of action and may range from severe to fatal. Examples of immune-mediated adverse reactions that occurred during the study included pneumonitis, colitis, hepatitis, adrenal insufficiency, hypophysitis, hypothyroidism, hyperthyroidism, type 1 diabetes mellitus, nephritis with renal dysfunction, and immune-mediated dermatologic reactions.\textsuperscript{14} It is important to monitor for immune-mediated adverse reactions and address them immediately once detected.

Other PD-1 Inhibitors—Although PD-1 inhibitors have been studied in advanced SCCs, their clinical data are limited for BCCs.\textsuperscript{17} Prior to 2018, there was a small number of case reports of patients with BCC with partial to exceptional response to PD-1 inhibitors. Recently, 2 additional case reports were published with contrasting outcomes using 2 different PD-1 inhibitors. An elderly patient with metastatic non–small cell lung cancer was treated with nivolumab after failing chemotherapy. She subsequently developed a BCC on the nose that was resected but recurred 2 months later despite continuing nivolumab.\textsuperscript{17} Another case report detailed a patient with a history of BCC on the shoulder excised 5 years prior who presented with recurrence on the sternum and clavicle.\textsuperscript{18} One year later the patient was found to have BCC metastases to the lung. After progression of disease despite vismodegib and recurrence of BCC with taladegib, the patient was then placed on pembrolizumab. At 6 weeks and 12 months, computed tomography showed resolution of multiple lung lesions. Sixteen weeks after initiation of pembrolizumab treatment, spinal metastases were found, but the treatment was continued because of the improvement in the lung metastases.\textsuperscript{18}

Taladegib—Taladegib is a SMO antagonist that has been through a phase 1 trial in patients with advanced cancer, including treatment-naive and previously treated BCCs.\textsuperscript{19} Eighty-four patients were treated to examine the safety profile and determine an appropriate phase 2 dose and administration schedule. The maximum tolerable dose was determined to be 400 mg because of dose-limiting toxicities. All clinical responses were in patients with BCCs (47/84 [55.9%] patients), with a response rate of 46.8%. Eleven of 16 (68.8%) Hh-treatment–naive patients and 11 of 31 (35.5%) patients previously treated with Hh responded to taladegib. Common adverse events were dysgeusia, fatigue, nausea, and muscle spasms.\textsuperscript{19} Although vismodegib is an FDA-approved SMO antagonist since 2012, treatment resistance and tolerability issues have been continuing concerns.\textsuperscript{20,21} Taladegib is a potential alternative that may be found to have improved pharmacodynamics and pharmacokinetics. Not only did in vitro studies show a preferable protein-binding profile with taladegib, but it also displayed dose proportionality, while vismodegib has been known to have nonlinear pharmacokinetics.\textsuperscript{19}

Posaconazole—Posaconazole is a systemic antifungal agent that is a structural analogue to itraconazole.\textsuperscript{22} Itraconazole has been found to inhibit the Hh pathway as an SMO antagonist. In a study with mice, posaconazole was found to have strong activity against drug-resistant SMO mutants while inhibiting the growth of Hh-dependent BCCs in vivo. A marked decrease also was seen in the ciliary accumulation of SMO, suggesting a similar mechanism of action to itraconazole. Posaconazole’s use for BCCs currently is limited to basic science studies.
but may offer a potential alternative to itraconazole, which is known to have many drug-drug interactions and requires dose adjustments in renal and hepatic insufficiency. When used as an antifungal compared to itraconazole, posaconazole has a favorable long-term safety profile due to fewer drug-drug interactions and mild side effects; it also does not require dose adjustments in mild to moderate renal or hepatic insufficiency.\textsuperscript{25} Thus, posaconazole is a potentially safer alternative to itraconazole for the treatment of BCCs. Although phase 2 studies of itraconazole for BCCs have shown decreased cell proliferation, tumor size, and reduced GLI1 messenger RNA, side effects included fatigue and grade 4 heart failure.\textsuperscript{23,24}

**Radiation Therapy**

Radiation therapies (RTs), such as superficial RT, have been long-established treatment options.\textsuperscript{25} However, there also are emerging methods of delivering RT, including electronic brachytherapy (EB). Although there is a low likelihood of residual tumor after RT given the number of sessions involved and the more aggressive nature of the treatment, these factors also can be a substantial burden on the patient. Furthermore, RT may result in subsequent scar tissue, which can hinder the use of other emerging technologies, such as noninvasive imaging devices, following RT.

**Superficial RT**—Superficial RT is a secondary option for the treatment of NMSC for use in special circumstances, such as when surgical intervention is contraindicated or refused, and after the benefits and risks of treatment alternatives have been discussed.\textsuperscript{26} However, depending on the tumor type and anatomical location, 6 to 18 treatments may be required, with treatment frequency ranging from 1 to 5 treatments per week.\textsuperscript{33} Patients may find this treatment regimen difficult to maintain given the length of time and frequency of treatments required. Side effects include radiation dermatitis and postinflammatory hypopigmentation or hyperpigmentation in patients with dark skin, and there is a risk for recurrence.\textsuperscript{25,27}

**Electronic Brachytherapy**—Brachytherapy is a method of delivering RT via radioactive isotopes, whereas EB uses lower-energy photons that require less shielding.\textsuperscript{28} As a relatively new therapy, studies on the efficacy of EB on NMSC continue to grow but with limited data comparing EB with established treatments. Furthermore, there are limited long-term follow-up data, and future studies should expand the patient demographic to younger patients before treatment guidelines can be established.\textsuperscript{28}

**RT With Concurrent and Adjuvant Vismodegib**—Vismodegib is an SMO inhibitor that was FDA approved in 2012 for the treatment of locally advanced BCC in patients who are not candidates for surgery or RT.\textsuperscript{29} Over time, studies have looked into other indications for vismodegib, such as a neoadjuvant to MMS or in patients with NBCC syndrome.\textsuperscript{11} Prior to 2018, there were only 2 known case reports of concurrent vismodegib and RT used for recurrent advanced BCC.\textsuperscript{30} Recently, vismodegib has been further examined in combination with RT in a case report,\textsuperscript{31} basic science study,\textsuperscript{32} and phase 2 trials (ClinicalTrials.gov Identifiers NCT02956889 and NCT01835626).

Prior studies showed low cure rates with vismodegib alone after RT (43%) as well as decreasing cure rates with primary RT alone as tumor size increased.\textsuperscript{33,34} In 2018, vismodegib was used concurrently and as an adjuvant to RT in a patient with advanced multifocal BCC.\textsuperscript{31} The patient had multiple large BCCs on the trunk that were painful and bleeding. The patient was started on RT and 150 mg/d vismodegib concurrently, which was then continued adjuvantly for 3 months until it was discontinued because of diarrhea. The patient had complete response in all lesions with resolution of symptoms.\textsuperscript{31} A separate basic science study further supported the potential role of vismodegib in radiation sensitization of both BCCs and head and neck SCCs.\textsuperscript{32} There presently are 2 phase 2 trials investigating the concurrent use of vismodegib and RT, which could help determine the efficacy of the combined approach for patients with advanced BCCs who are poor surgical candidates (NCT02956889 and NCT01835626).

**Photodynamic Therapy**

Photodynamic therapy has been in use since the 1970s when Dougherty et al\textsuperscript{35} performed one of the first studies on its use in skin cancer. Since then, PDT has been used for the treatment of actinic keratoses (AKs) and more recently BCCs. In PDT, a photosensitizer (PS) is applied and activated by a 400-nm blue light or 635-nm red light, depending on the PS used. The PS then produces highly reactive oxygen species, leading to apoptosis of the cancer cells.\textsuperscript{36} In Europe, red light PDT is licensed for the treatment of AKs as well as superficial and nodular BCCs, though approved indications vary between countries. In the United States, PDT is only FDA approved for the treatment of AKs.\textsuperscript{37}

**Aminolevulinic Acid Hydrochloride**—Aminolevulinic acid hydrochloride is a red light PS used to treat AKs since 2011 and BCCs since 2017 in Europe in addition to AKs in the United States since 2016.\textsuperscript{38,39} A phase 3 noninferiority clinical trial in Europe of 281 patients compared the treatment of nonaggressive BCCs with ALA to methyl aminolevulinate (MAL) cream.\textsuperscript{40} The trial found a complete response rate of 93.4% vs 91.8%. Superficial BCCs treated with ALA had a clearance rate of 94.7% vs 96.4% with MAL, while nodular BCCs treated with ALA had a clearance rate of 85.7% vs 76.2% with MAL. A 1-year clinical follow-up showed similar recurrence rates (8.4% for ALA vs 8.5% for MAL).\textsuperscript{40} The results of this study led to an expanded indication in Europe to include the treatment of BCCs. Aminolevulinic acid hydrochloride currently is undergoing phase 3 clinical trials in the United States for approval for the treatment of superfi- cial BCCs (NCT03573401). If similar outcomes are achieved, US patients may have access to an alternative nonsurgical treatment of BCCs. The ongoing US trial is exclusively
investigating the efficacy and safety for superficial BCCs, which may limit FDA approval to only superficial BCCs, accounting for only 8.4% to 24.1% of all BCCs.\textsuperscript{35,41,42}

**Laser Therapy**

Ablative and nonablative lasers have been used to treat NMSCs in the literature. Ablative lasers destroy tumors through vaporization of tissue water, whereas nonablative lasers target the vasculature of tumors while preserving the surrounding tissue.\textsuperscript{3,14} Nonablative lasers include pulsed dye lasers (PDL) and Nd:YAG lasers. Examples of ablative lasers include CO\textsubscript{2} and erbium:YAG lasers. Given the status of lasers as an emerging treatment method, there currently is no standardized laser setting for any of the laser therapies used to treat NMSCs. Although there is the potential for optimal cosmetic outcomes and a limited side-effect profile for nonablative laser therapies, there are limited data on long-term follow-up to study recurrence rates and establish a more standardized treatment protocol.

**Pulsed Dye Lasers**—Although there were no studies on PDL therapy alone in 2018, a study published in 2019 evaluated a combination laser treatment using a 595-nm PDL and 1927-nm fractional laser for the treatment of 93 BCCs, yielding a 95.7% (89/93) clearance rate and 4.5% (4/89) recurrence rate over a follow-up period of up to 6 years (range, 2.53 months to 6.03 years).\textsuperscript{45} Studies of PDL prior to 2018 had follow-ups ranging from 2 weeks to 6 months.\textsuperscript{46-51} Although the majority were biopsy-proven BCCs, reflectance confocal microscopy also was used for same-day diagnoses. Long-term follow-up included clinical examinations, dermoscopy, and optical coherence tomography.\textsuperscript{45} The clearance rate (95.7%) using noninvasive imaging in conjunction with the combination laser treatment was superior to both histologic and clinical clearance rates of prior PDL-only studies, which ranged from 25% to 95%.\textsuperscript{46-51} To have long-term follow-up data, the study used noninvasive imaging with clinical follow-up because histology would not be viable for long-term follow-up. This study was retrospective rather than prospective, which was a limitation.\textsuperscript{45}

**Nd:YAG Lasers**—The majority of studies utilizing Nd:YAG lasers investigated their efficacy in treating BCCs, with the exception of 1 study of facial SCCs. This major study in 2009 of 627 BCCs showed a 2.5% recurrence rate after a follow-up time of 3 months to 5 years.\textsuperscript{52} Nd:YAG lasers continue to be investigated, including a more recent study of 31 extracelial, biopsy-proven BCCs that were treated with the 1064-nm Nd:YAG laser, which showed a 90% histologic clearance on 1-month follow-up after a single treatment.\textsuperscript{39} In 2019, a retrospective review of 16 BCC lesions on the face, neck, trunk, and extremities showed 100% clearance after 1 treatment, with an average follow-up period of 9 months (range, 6–15 months).\textsuperscript{34} In a retrospective review, Markowitz and Psomadakis\textsuperscript{35} contributed data supporting the further investigation and use of the 1064-nm Nd:YAG laser for BCC treatment while leveraging noninvasive imaging to demonstrate a same-day management model. Seventeen BCC lesions on the face and body were diagnosed by reflectance confocal microscopy and treated with an Nd:YAG laser, and clearance was monitored clinically, dermoscopically, and by optical coherence tomography. There was 100% clearance of the lesions in the study, with 82.4% (14/17) clearing after 1 treatment; mean follow-up was 103 days (range, 48–371 days).\textsuperscript{53} These studies were limited by their short follow-up time; long-term data are needed to determine true rates of recurrence.

**Ablative Lasers**—Ablative lasers also have been used in the treatment of NMSCs. In addition to the potentially increased healing time compared to nonablative lasers, other limitations of ablative laser therapy include residual tumor burden or recurrence that may not be easily visualized in scarred tissue after non ablative management.\textsuperscript{44}

**Conclusion**

Although MMS remains the gold standard for invasive management of NMSCs, studies from 2018 and beyond (eTable) expanded not only on MMS topics such as increased patient access and improved techniques but also on the increasing potential of noninvasive treatments. Some of the noninvasive therapies were entirely new compounds, whereas others were already in use for a different disease indication. Furthering our knowledge and expanding our repertoire of management options will prepare us as the number of patients affected by NMSCs increases.

**REFERENCES**

EMERGING THERAPIES FOR NMSC


## Studies of Emerging Noninvasive Treatments for Nonmelanoma Skin Cancers

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tumor Type</th>
<th>Dosing/Duration</th>
<th>Study Type</th>
<th>No of Treated Lesions</th>
<th>Response/Clearance Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sonidegib	extsuperscript{13}</td>
<td>BCC (NBCC syndrome)</td>
<td>0.75% cream twice daily for 4 wk</td>
<td>RCT</td>
<td>13</td>
<td>23.1% complete response, 69.2% partial response, 7.7% no response</td>
</tr>
<tr>
<td>Cemiplimab	extsuperscript{16}</td>
<td>Advanced SCC</td>
<td>3 mg/kg every 2 wk for up to 48 wk</td>
<td>Phase 1 clinical trial</td>
<td>26</td>
<td>50% response</td>
</tr>
<tr>
<td></td>
<td>Metastatic SCC</td>
<td>3 mg/kg every 2 wk for up to 96 wk</td>
<td>Phase 2 clinical trial</td>
<td>59</td>
<td>47.5% response</td>
</tr>
<tr>
<td>Taladegib	extsuperscript{19}</td>
<td>Advanced BCC</td>
<td>400 mg was found to be the maximum toxicity dose</td>
<td>Phase 1 clinical trial</td>
<td>47</td>
<td>68.8% (HhI-naive patients) response, 35.5% (HhI-treated patients) response</td>
</tr>
<tr>
<td>Posaconazole	extsuperscript{22}</td>
<td>BCC</td>
<td>Dose tested for pharmacokinetics was 30 mg/kg twice daily</td>
<td>Mouse study</td>
<td>N/A</td>
<td>Inhibited SMO with a distinct mechanism from current SMO antagonists</td>
</tr>
<tr>
<td>RT + vismodegib	extsuperscript{3,32}</td>
<td>Advanced BCC</td>
<td>150 mg/d vismodegib concurrent to RT + 150 mg/d vismodegib for 3 mo after RT</td>
<td>Case report</td>
<td>5</td>
<td>100% response</td>
</tr>
<tr>
<td></td>
<td>Head and neck BCC and SCC</td>
<td>N/A</td>
<td>Basic science</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Aminolevulinic acid hydrochloride	extsuperscript{40}</td>
<td>Superficial and nodular BCC</td>
<td>2 PDT sessions separated by 1 wk</td>
<td>Phase 3 clinical trial in Europe</td>
<td>281</td>
<td>93.4% clearance</td>
</tr>
<tr>
<td></td>
<td>Superficial BCC</td>
<td>2 PDT sessions separated by 1–2 wk</td>
<td>RCT</td>
<td>N/A</td>
<td>Ongoing (ClinicalTrials.gov Identifier NCT03573401)</td>
</tr>
<tr>
<td>595-nm PDL + 1927-nm fractional laser	extsuperscript{46}</td>
<td>BCC</td>
<td>Treatment every 2 mo until clearance on OCT; PDL parameters: 6–15-J/cm² fluence, 0.45–3-ms pulse duration, 7–10-mm spot size; fractional laser parameters: 5–20-mJ fluence, 40%–70% treatment density</td>
<td>Retrospective review</td>
<td>93</td>
<td>95.7% clearance</td>
</tr>
<tr>
<td>1064-nm Nd:YAG laser	extsuperscript{63–66}</td>
<td>Extracutaneous BCC</td>
<td>Parameters: 1 treatment, 7–10-ms pulse duration, 5-mm margin, 5–6-mm spot size, 125–140-J/cm² fluence, no cooling</td>
<td>Prospective review</td>
<td>31</td>
<td>90% clearance</td>
</tr>
<tr>
<td></td>
<td>BCC</td>
<td>Parameters: 1 treatment, 8-ms pulse duration, 140-J/cm² fluence, 5-mm spot size</td>
<td>Retrospective review</td>
<td>16</td>
<td>100% clearance</td>
</tr>
<tr>
<td></td>
<td>BCC</td>
<td>Treatment every 2 mo until clearance on OCT; parameters: 125–140-J/cm² fluence, 7–10-ms pulse duration, 5–6-mm spot size</td>
<td>Retrospective review</td>
<td>17</td>
<td>100% clearance</td>
</tr>
</tbody>
</table>

Abbreviations: BCC, basal cell carcinoma; NBCC, nevoid basal cell carcinoma; RCT, randomized controlled trial; SCC, squamous cell carcinoma; HhI, hedgehog inhibitor; N/A, not applicable; SMO, smoothened; RT, radiation therapy; PDT, photodynamic therapy; PDL, pulsed dye laser; OCT, optical coherence tomography.